Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006-Reference-Cited by-同舟云学术

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

Published:2018-09 Issue:6 Volume:119 Page:670-674
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Hamid Omid,Robert Caroline,Ribas Antoni,Hodi F. Stephen,Walpole Euan,Daud Adil,Arance Ana S.,Brown Ewan,Hoeller Christoph,Mortier Laurent,Schachter Jacob,Long Jianmin,Ebbinghaus Scot,Ibrahim Nageatte,Butler Marcus

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0207-6.pdf

Reference11 articles.

1. McLaughlin, C. C. et al. Incidence of noncutaneous melanomas in the U.S. Cancer 103, 1000–1007 (2005).

2. Patrick, R. J., Fenske, N. A. & Messina, J. L. Primary mucosal melanoma. J. Am. Acad. Dermatol. 56, 828–834 (2007).

3. Shreders, A. & Joseph, R. W. Efficacy of immunotherapy for metastatic mucosal melanoma. Immunotherapy 8, 843–845 (2016).

4. Chang, A. E., Karnell, L. H. & Menck, H. R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 83, 1664–1678 (1998).

5. Yamazaki, N. et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother. Pharmacol. 79, 651–660 (2017).

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment outcomes of vulvar and vaginal melanoma at an NCCN institution between 1993 and 2021;Gynecologic Oncology Reports;2024-10

2. Expression of immune checkpoint molecules TIGIT and TIM-3 by tumor-infiltrating lymphocytes predicts poor outcome in sinonasal mucosal melanoma;Pathology - Research and Practice;2024-08

3. Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1–resistant mucosal melanoma;Melanoma Research;2024-06-28

4. Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions;Current Oncology Reports;2024-06-07

5. Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma;Journal for ImmunoTherapy of Cancer;2024-06